Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)

Dermatology Online Journal

Volumn 12, Issue 7, 2006, Pages

  Cecchi, Roberto ^a   Bartoli, Laura ^a  

^a Spedali Riuniti ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; LIVER ENZYME; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG SAFETY; HEPATITIS C; HUMAN; MALE; MONOTHERAPY; PSORIASIS VULGARIS; REVIEW; SUPERINFECTION; TREATMENT OUTCOME; VIRUS LOAD; ARTICLE; COMORBIDITY; DRUG ANTAGONISM; MIDDLE AGED; PSORIASIS;

BIOLOGICAL RESPONSE MODIFIERS; COMORBIDITY; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 33845669833     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat. 2003 Dec; 14(4): 229-32.
2. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004 Oct; 51(4): 580-4.
3. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29; 356(9227): 385-90.
4. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997 Dec; 42(12): 2487-94.
5. Nasir A, Arora HS, Kaiser HE. Apoptosis and pathogenesis of viral hepatitis C: an update. In Vivo. 2000 Jan-Feb; 14(1): 297-300.
6. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004 Nov; 63 Suppl 2:ii18-ii24.
7. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis.2003 Nov; 62(11): 1078-82.
8. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005 Mar; 42(3): 315-22.
9. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006 Feb; 54(2): 361-2.
10. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol. 2006 Jun; 54(6): 1102-4.